Home MarketAarti Drugs Ltd.

Aarti Drugs Ltd. Stock Info: As on 2018-05-24 15:44:43

Nse

533.05

1.10(0.21%)
Change%
52 Week Range
447.80
24.00
785.00
9.00
Open533.20
Day's Range425.56 - 638.34
Value Traded (in ₹ Cr.) 0.13

Bse

530.00

0.85(0.16%)
Change %
52 Week Range
456.25
24.00
784.80
9.00
Open538.00
Day's Range423.32 - 634.98
Value Traded (in ₹ Cr.) 0.02

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 14,734,407.00 62.48%
Mutual Funds/UTI 867,580.00 3.68%
FII 188,113.00 0.80%
Employee 0.00 0.00%
Public 6,725,910.00 28.52%
Government 0.00 0.00%
Others 861,742.00 3.65%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 1.26
Basic EPS (Rs.) 30.78
Cash EPS 46.50
BVPerShare Excl 166.64
Operating Revenue 457.83
PBDITPerShare 74.49
Dividend 1.00
NPPerShare 31.12
Current Ratio 1.18
Quick Ratio 0.75
PriceToBV 3.45
Earnings 0.05
PBDIT Margin 16.27
PBT Margin 9.75
NP Margin 6.79
Return On Assets 6.73
Retention Ratios 0.00
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 1,092.26
Total Expenses 985.72
EBITDA 177.72
PBT 106.54
PAT 74.24
Net Income 74.24
More
Parameter Mar-18 (₹ Cr.) 6M % change
Total Income 624.23
Total Expenses 537.62
EBITDA 67.56
PBT 69.66
PAT 44.81
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 23.86
Net worth 397.55
Investments 10.03
Total Liability 1,102.46
Total debt 417.02
Net block 556.45
Total Assets 1,102.46
Parameter Mar-17 (₹ Cr.) 6M % change
Total share capital 24.22
Net worth 350.31
Investments 11.12
Total Liability 1,054.70
Total debt 432.58
Net block 496.81
Total Assets 1,054.70
Company Curr Price Prev. Close Change% W's Low/High

Abbott India Ltd.

6671.7 6587.45 1.28
65106890

Ajanta Pharma Ltd.

977.6 987 -0.95
962.351074.5

Albert David Ltd.

362.35 362.75 -0.11
356.2383.15

Alembic Ltd.

48.85 50.8 -3.84
50.254

Alembic Pharmaceuticals Ltd.

420.7 422.3 -0.38
418.5491.2

Alkem Laboratories Ltd.

1957.55 1965.35 -0.4
18882036.65

Alpa Laboratories Ltd.

32.1 32.55 -1.38
31.5534.4
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16
46.351.55

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83
4355

Abbott India Ltd.

6699.95 6593.7 1.61
6465.056872.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3

Advik Laboratories Ltd.

3.95 3.85 2.6
3.64.19
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 174.21
Cash from investing activities -96.29
Cash from financing activities -78.42
Net change in cash -0.50

Stock Held By Mutual Fund Schemes

M Venkatesh appointed MRPL MD

M Venkatesh has been appointed as the Managing Director of Mangalore Refineries and Petrochemicals Limited (MRPL), an order issued by the Personnel Ministry said today. Vekatesh is at present Director (Refineries) in the MRPL, a subsidiary of the Oil and Natural Gas Corporation Limited (ONGC) He has been appointed to the post for a period of five years with effect from the date of his assumption of charge of the post on or after June 1, 2018, or till the date of his superannuation, the order said.

24-05-2018 11:42

TCS expands operations in Florida as part of Transamerica deal

India's largest IT services firm TCS today said it has expanded operations in Florida, US, with over 430 employees joining the company as part of its deal with Transamerica. In January, Tata Consultancy Services (TCS) had signed an over USD 2 billion deal with Transamerica to administer the latter's life insurance, annuity, supplemental health insurance, and workplace voluntary benefits products. It covered managing administration of more than 10 million policies. More than 430 former Transamerica employees now work for TCS at this new St Petersburg facility (in Florida) as part of recruiting and investing in more than 2,200 Transamerica jobs across the US in multiple locations, the Indian software services giant said in a statement. TCS will occupy several floors of Transamerica's building at 570 Carillon Parkway in St Petersburg, as part of a multi-year agreement with Transamerica... The St Petersburg office is a new US business centre for TCS, adding to the over 1,000 employees already serving American businesses throughout the state, it added. TCS said it has invested nearly USD 3 billion in the US over the past three years and has been among the top two IT services job creators in the country. TCS is a leading industry employer in the US, striving to help American companies like Transamerica to digitally transform their business and capitalise on rapidly evolving customer demands, TCS President and Global Head (Banking, Financial Services and Insurance Platforms) Suresh Muthuswami said. We look forward to partnering with St Petersburg's city, state and local organizations to further build upon our business and community impact, he added. The company said it has made tremendous community impact in Florida over past several years.

24-05-2018 11:16

Kotak India Growth Fund Series 4 - Direct Plan: change in investment factsheets for April

Kotak India Growth Fund Series 4 - Direct Plan has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.89 for Growth, while 52-Week High and Low ranges were Rs 10.35 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 - Direct Plan is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

Kotak India Growth Fund Series 4: change in investment factsheets for April

Kotak India Growth Fund Series 4 has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.88 for Growth, while 52-Week High and Low ranges were Rs 10.34 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

BLS International to assist Sopra Steria on UK visa renewals

Visa service provider BLS International today said theUnited Kingdom Visas and Immigration (UKVI) has awarded Sopra Steria a new contract to enable visa renewals for those individuals who are already in the UK. BLS International will support Sopra Steria and UKVI, a division of the UK Home Office responsible for deciding who can visit and stay within the UK, by establishing and delivering some of the key add value services under the contract, it said in a release. BLS International claims to handle about 12 million visa applications annually across the globe at present. Meanwhile, shares of the company were trading at Rs 172.55 apiece, up 1 per cent from the previous close at 10:50 hours on BSE.

24-05-2018 10:51

Aarti Drugs Ltd - Clarification - Financial Results

The Exchange has sought clarification from Aarti Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.

18-May-2018 12:31 PM

Aarti Drugs Ltd Q4 net profit up 11.34% at Rs 22.78 cr

The company reported standalone net profit of Rs 22.78 crore for the quarter ended March 31, 2018 as compared to Rs 20.46 crore in the same period last year, registering a year-on-year growth of 11.34 per cent. Net revenue of the company rose moderately by 16.83 per cent at Rs 314.99 crore in January-March quarter of this fiscal as against Rs 269.62 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 15.62 per cent to Rs 261.15 crore from Rs 225.87 crore in year ago period. Other Income grew by 0.00 per cent at Rs 0.90 crore versus (Mar'17 Rs 0.00 crore). Operating Profit surged by 17.43 per cent to Rs 53.84 crore as against Rs 45.85 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 0.47 per cent in March quarter. Interest grew by 5.19 per cent y-o-y to Rs 8.51 crore, while Taxation increased by 60.47 per cent at Rs 13.80 crore (Mar'17 Rs 8.60 crore).

17-May-2018 05:15 PM

Aarti Drugs Ltd - Press Release

Aarti Drugs Limited has informed the Exchange regarding a press release dated May 16, 2018, titled Press Release .

16-May-2018 06:34 PM

Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release for the Quarter ended 31.03.2018.

16-May-2018 06:31 PM

Aarti Drugs Ltd - Dividend

Aarti Drugs Limited has informed the Exchange that the Board of Directors of the Company at its meeting held May 16, 2018 have recommended a final dividend @ Rs. 1 (10%) per share of Rs. 10/-each for the Financial year ended 2017-2018.

16-May-2018 03:06 PM

Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release for the Quarter ended 31.03.2018.

16-May-2018 06:31 PM

Aarti Drugs Ltd - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

16-May-2018 02:51 PM

Aarti Drugs Ltd - Corporate Action-Board approves Dividend

Compliance of Regulation 30 & 43 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

16-May-2018 02:49 PM

Corporate Details

About Management

Aarti Drugs Limited was incorporated on 28th September, 1984 as a Private Limited Company. It was converted into a Public Limited Company on 1st July, 1992. The Company is presently engaged in the manufacture of MNI(300 TPA), MTZ (96 TPA), TNZ (84 TPA), DMZ (90 TPA) and Isoniazid (INH) (96 TPA). The Company started its commercial production is March 1987 at G.I.D.C. Industrial Estate, Sarigam, Dist. Valsad, Gujarat. This project was put up with financial assistance from Gujarat State Finance Corporation (GSFC) and Gujarat Industrial Investment Corporation (GIIC). The Company now proposes to expand the capacities for the above products, except INH and also proposes to set up a new plant for the manufacture of Glyoxal and Ammonium Sulphate. The Company has been consistently making profits and has maintained an unbroken dividend record since the year 1990-91. The Company is a part of the Alchemie Group of Companies. The Company is promoted by Mr. Chandrakant V.Gogri, Mr.Rajendra V.Gogri and Mr. Shantilal T. Shah. Mr. P.M. Patil and Mr. S. P. Nachane joined the Group in 1981. The Alchemie Group is a professionally managed, multi-product, multilocation Group comprising 24 manufacturing units with a total turnover of over Rs.100 crores for the year 1991-92. The products of the Group, exceeding 40, range from industrial chemicals and dye intermediates to bulk drugs and fine chemicals. The Group's customer list includes most of the leading chemical companies in the country. The Group's turnover and profits have increased five-fold in the last 5 years. It also recorded an export turnover of more than Rs. 30 crores in the year 1991-92. The Group units export products mainly to the general currency areas such as USA, UK, Switzerland and Germany. 2000 - The Company proposed to acquire 15,31,000 No. of equity shares of Alchemie Organics Ltd 33.44 per cent of the total paid-up capital of AOL held by the other promoters. 2002-Gauri Balankhe appointed as Compliance Officer of Aarti Drugs. 2004 -Aarti Drugs Ltd. has informed that the Company has changed its Registrar and Share Transfer Agent and Depository interface for Handling Depository related operations by appointing M/s Sharepro Services in place of M/s R & D Consultants Ltd w.e.f. January 16, 2004 subject to completion of necessary formalities as maybe prescribed in this regard. The address and telephone number of M/s Sharepro Services for all investors related services are as under: 1. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai 400 021, Tel nos : 22881569, 22884527. 2. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Satam Estate, 3rd Floor, Above Bank of Baroda, Chakla, Andheri (East), Mumbai 400 099, Tel nos : 28215168, 28319828; Fax nos : 28375646. -Aarti bags European certification for three drugs -Delist from Ahmedabad Stock Exchange (ASE) with effect from October 15, 2004. 2006 -Aarti Drugs enters into JV with API Manufacturing Chinese Company - Aarti Drugs Ltd. has informed that Mr. Prakash Khedekar, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from October 31, 2006. Further, Mrs. Mona Patel, possessing requisite qualifications, has been appointed as Company Secretary & Compliance Officer of the Company with effect from November 01, 2006. 2009 - Aarti Drugs Ltd has has appointed Shri Krishnacharya Govindacharya Akamanchi & Prof. Sudhir Prakash B. Sawant as Independent Directors of the Company. 2010 -Aarti Drugs has recommended dividend of Rs. 5/- (50%) per share 2011 -Mr. Sunny D. Pagare, has been appointed as Company Secretary & Compliance Officer of the Company -Aarti Drugs has recommended Final Dividend of Rs. 2.5 /-per share (25%) 2012 -Mr. Adhish P. Patil, has been appointed as Chief Financial Officer of the Company -Aarti Drugs has declared Final dividend Rs. 3.00 (30%) per share 2013 -Aarti Drugs has recommended a Final Dividend of Rs. 4/- per share on Equity Shares of Rs. 10/- each. 2014 -Aarti Drugs has commenced the new R&D center at MIDC Tarapur. -Aarti Drugs has recommended a Final dividend @ Rs. 5.50 ps. (55%) per share. 2015 -Aarti Drugs Ltd has will participate at 'Centrum Pharma Day' Investor Conference -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 1:1.

Registered Office

Plot Nos. D-277/278, TTC Industrial Area, Turbhe

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.